Loading...
Mayne Pharma Group Limited
MAYNF•PNK
Healthcare
Drug Manufacturers - General
$1.86
$0.005(0.27%)
U.S. Market opens in 6h 50mMayne Pharma Group Limited (MAYNF) AI-Powered Stock Analysis
See how Mayne Pharma Group Limited scores across key metrics like financial growth, valuation, and market position using AI-driven evaluation.
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continously improving this model to increase accuracy and performance.Read our Full DisclaimerMayne Pharma Group Limited (MAYNF) Stock Overall Grade
Mayne Pharma Group Limited’s grade based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
Z
Grade Breakdown by Metric
See how each financial and market factor contributes to Mayne Pharma Group Limited's overall stock rating.
Forecast
C+Score
55/100Financial Growth
BScore
65/100Fundamental Growth
DScore
33/100Key Ratios
BScore
60/100Sector Comparison
A+Score
100/100Industry Comparison
C+Score
50/100S&P 500 Benchmark
A+Score
95/100Analyst Consensus
C+Score
50/100Mayne Pharma Group Limited (MAYNF) AI-Powered Stock Analysis
This asset demonstrates Good performance with an overall Forecast Score of 55/100 (C+), reflecting weak confidence in its potential. Financial Growth (65/100, B) and Fundamental Growth (33/100, D) highlight its stability, while Key Ratios (60/100, B) and Sector Comparison (100/100, A+) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (95/100, A+), it shows competitive strength. Analyst Consensus (50/100,C+) suggests High divergence in outlook.Component Analysis Explained
Understand the key factors behind each Mayne Pharma Group Limited stock grade, including financials, comparisons, and forecasts.